9 Biotechnology Stocks to Buy Now

Advertisement

This week, nine biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, Stemline Therapeutics, Inc. (STML) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc. (PCYC) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

Acorda Therapeutics, Inc.’s (ACOR) ratings are looking better this week, moving up to a B from last week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

This week, Northwest Biotherapeutics, Inc. (NWBO) pushes up from a C to a B rating. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

Agios Pharmaceuticals, Inc. (AGIO) improves from a C to a B rating this week. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

BioMarin Pharmaceutical (BMRN) shows solid improvement this week. The company’s rating rises from a C to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

This is a strong week for Seattle Genetics, Inc. (SGEN). The company’s rating climbs to B from the previous week’s C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Bluebird Bio, Inc. (BLUE) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of BLUE stock.

Amgen (AMGN) boosts its rating from a B to an A this week. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/08/9-biotechnology-stocks-to-buy-now-stml-pcyc-acor/.

©2024 InvestorPlace Media, LLC